Shocking Lyme Disease Vaccine Results: 70% Efficacy Could Change Everything—Will You Be Protected?

An experimental Lyme disease vaccine developed by Pfizer in collaboration with Valneva has shown promising results in preventing the disease, demonstrating over 70% efficacy in individuals aged five years and older, according to a statement released yesterday. The vaccine, known as PF-07307405 (LB6V), was evaluated in a phase 3 randomized controlled clinical trial, though it fell short of its primary statistical goal due to a lower-than-expected number of Lyme disease cases during the study period. Despite this, the vaccine still achieved an efficacy rate ranging from 70% to 73% after a four-dose series.

The trial was conducted in regions of high Lyme disease incidence across the United States, Canada, and Europe. Pfizer has indicated that the reduction in infections is "clinically meaningful" and plans to submit the vaccine for regulatory approval. If approved, this would mark the first Lyme disease vaccine available for humans in over 20 years.

How the Vaccine Works

The multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the Borrelia burgdorferi bacteria, the causative agent of Lyme disease. When vaccinated, a person develops antibodies that are ingested by ticks during feeding. These antibodies bind to OspA within the tick, effectively blocking the bacteria from entering the human bloodstream. The vaccine is designed to protect against the six most prevalent forms of OspA found in Lyme-causing bacteria across North America and Europe.

The vaccine prevents the bacteria from leaving the tick and entering the human bloodstream.

"Lyme disease can cause potentially serious consequences—where individuals and families face symptoms that can disrupt daily life, work, and long-term health—and there is currently no vaccine available," stated Dr. Annaliesa Anderson, Senior Vice President and Chief Vaccines Officer at Pfizer. "The efficacy shown in the VALOR study of more than 70% is highly encouraging and creates confidence in the vaccine’s potential to protect against this disease that can be debilitating."

While the new vaccine shows promise, the history of Lyme disease vaccines in the U.S. raises concerns. The previous vaccine, LYMERix, was approved in 1998 and reported to reduce infections by as much as 76%. However, public anxiety over potential adverse reactions led to a significant drop in sales, and GSK (formerly GlaxoSmithKline) withdrew it from the market in 2002 due to low consumer demand.

This new Pfizer/Valneva vaccine is likely to encounter increased scrutiny in a climate of rising vaccine skepticism. Under the leadership of Robert F. Kennedy Jr., the Department of Health and Human Services has adopted an anti-vaccine stance, dismantling federal immunization advisory boards and reshaping them with skeptics. A recent federal court ruling blocked the Trump administration’s proposed changes to the childhood vaccine schedule, underscoring the contentious atmosphere surrounding vaccination.

In addition to the Pfizer/Valneva vaccine, Moderna is also developing an mRNA-based Lyme vaccine, with recruitment for its phase 1/2 trial currently underway. It’s worth noting that while humans have been without a Lyme vaccine for over two decades, a Lyme disease vaccine for dogs has been available since 2016.

According to the Centers for Disease Control and Prevention, approximately 476,000 patients are diagnosed with Lyme disease in the United States each year. The disease is caused by B. burgdorferi spirochetes, transmitted to humans via specific tick species, notably black-legged or deer ticks. If not treated promptly, Lyme disease can lead to severe health complications, affecting multiple organ systems and resulting in long-term issues such as heart problems, chronic inflammation, joint pain, and neurological disorders.

Most Lyme disease cases in the U.S. occur in the Upper Midwest and along the northeastern seaboard, while ticks carrying B. burgdorferi are also found in parts of Central and Northern Europe. Lyme disease remains the most common vector-borne illness in the Northern Hemisphere, making the development of effective vaccines all the more crucial as incidence rates rise.